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Abstract 
Pituitary adenylate cyclase-activating peptide (PACAP) is a neuropeptide implicated in a wide 
range of functions, such as nociception and in primary headaches. Regarding its localization, 
PACAP has been observed in the sensory trigeminal ganglion (TG), in the parasympathetic 
sphenopalatine (SPG) and otic ganglia (OTG), and in the brainstem trigeminocervical 
complex. Immunohistochemistry has shown PACAP-38 in numerous cell bodies of 
SPG/OTG, co-stored with vasoactive intestinal peptide (VIP), nitric oxide synthase (NOS) 
and, to a minor degree, with choline acetyltransferase. PACAP has in addition been found in a 
subpopulation of calcitonin gene-related peptide (CGRP)-immunoreactive cells in the 
trigeminal system. The PACAP/VIP receptors (PAC1, VPAC1, and VPAC2) are present in 
sensory neurons and in vascular smooth muscle related to the trigeminovascular system. It is 
postulated that PACAP is involved in nociception. In support, abolishment of PACAP 
synthesis or reception leads to diminished pain responses, whereas systemic PACAP-38 
infusion triggers pain behavior in animals and delayed-type migraine-like attacks in migraine 
patients without marked vasodilatory effects. In addition, increased plasma levels have been 
documented in acute migraine attacks and in cluster headache, in accordance with findings in 
experimental models of trigeminal activation. This suggest that the activation of the 
trigeminal system may result in elevated venous levels of PACAP, a change that can be 
reduced when headache is treated. The data presented in this review indicate that PACAP and 
its receptors may be promising targets for migraine therapeutics. 
Introduction 
Migraine is thought to involve a primary dysregulation of sensory processing, and much 
interest is focused on the central nervous system (CNS) as a starting point of migraine [1]. It 
is thought that the origin of the disease rests in the hypothalamus – thalamus system, coupling 
to the brainstem. The central involvement is reflected by many patients experiencing tactile 
allodynia and other neurological symptoms that affect the senses, including sensitivity to 
light, sound, and smell. These are thought to be consequences of central sensitization of the 
trigemino-thalamic pathway. The trigeminovascular system is involved with all its parts; the 
trigeminal nerve, the cranial vasculature, and nuclei within the brainstem/spinal cord. 
Pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide 
(VIP) are members of the VIP/secretin/growth hormone-releasing hormone/glucagon 
neuropeptide superfamily, widely expressed in vertebrate tissues [2-6]. VIP was first 
described by Victor Mutt during the early 1970s [7]. It was first isolated from pig intestine 
and is localized to most organs and tissues in the body. During the following years, the other 
members of the family were described and characterized, including peptide histidine 
isoleucine/methionine (PHI/PHM), secretin, and PACAP [3, 8, 9]. PACAP neuropeptide was 
discovered nearly 30 years ago based on its ability to enhance adenylate cyclase activity in rat 
pituitary cells, and was first isolated from ovine hypothalamic extracts [10]. Numerous studies 
on the localization/distribution/release of this group of neuropeptides from different tissues 
and involvement in diseases have been presented [11, 12]. The aim of this review is to focus 
on sensory aspects of PACAP and primary headaches, with special emphasis on migraine. 
General features and localization of PACAP within the CNS 
There are two forms of PACAP (–27 and –38), with both isoforms sharing functional and 
structural homologies with VIP [10] and being able to bind to G-protein-coupled receptors 
specific (PAC1) and less specific (VPAC1 and VPAC2; with comparable affinity to VIP, 
PACAP-27, and PACAP-38) to PACAP [3, 13, 14]. Recently, however, the functional 
presence of yet unidentified PACAP receptors have been proposed based on experimental 
results using selective modulators [15]. 
PACAP is a pleiotropic peptide that can be found in several exocrine and endocrine tissues, in 
the respiratory, intestinal, urinary, and reproductive systems, as well as in the central and 
peripheral nervous systems [16-23]. In neuronal tissues, the isoform PACAP-38 
predominates. It is known to play hypophysiotropic, neuromodulatory, and neurotransmitter 
roles, and has been associated with differentiation- and proliferation-inducing effects in the 
developing nervous system, as well as with cytoprotective, anti-apoptotic, and anti-
inflammatory features within various target organs [24-34]. Furthermore, PACAP has been 
shown to be a potent local and systemic vasodilator administered in a wide concentration 
range, associating with biphasic paradox hypertensive effects in very large doses [35-37]. 
Immunohistochemical evidence confirms the presence of PACAP in anatomical structures 
relevant to the pathogenesis of primary headaches including migraine, such as in the 
trigeminocervical system, including nerve fibers in the dura mater, the cerebral vessels [38], 
and the facial skin [39]; the trigeminal ganglion (TG) [15, 39-44]; the trigeminal nucleus 
caudalis (TNC) [15, 16, 45]; the Rexed 1 and 2 laminae at the C1-C2 levels of the cervical 
spinal cord [45]; in various brainstem nuclei within the ‘migraine generator area’ [16, 46, 47]; 
as well as the parasympathetic sphenopalatine (SPG) and otic ganglia (OTG) [40, 41, 48-50]. 
Recent works have revealed that PACAP is localized in small neurons in the dorsal root 
ganglia and the TG which in addition store calcitonin gene-related peptide (CGRP) [44]. 
Interestingly PACAP mRNA-labeled neurons constituted 10% of the total number of nerve 
cell bodies in the dorsal root ganglia, whereas the population of CGRP mRNA-labeled nerve 
cell bodies constituted 46% [51]. This agrees well with later immunocytochemical work on 
the TG [52]. 
In line with the above, early studies revealed the presence of specific PACAP-binding sites in 
relevant regions of the rat and human CNS [53, 54]. In addition, subsequent 
immunohistochemical and biochemical evidence demonstrated the presence of PAC1 and 
VPAC2 receptors in the rat TG [55]. Of note, there is functional [56] and biochemical data at 
the mRNA level suggesting that VPAC1 receptors are not present in the TG of rats, 
implicating possible species differences [55]. In agreement, mRNA for all three types of 
VIP/PACAP receptors have been reported to occur in human and rat TG [57], and this is 
supported by another study in the rat TG and TNC [15]. Moreover, protein expression has 
been shown by immunohistochemistry for all three types of PACAP receptors in both the 
human and rat SPG [49]. Suggesting a special role in terms of disease pathogenesis among 
relevant neuropeptides, detailed histochemistry revealed that while VIP/PACAP are both seen 
in the parasympathetic ganglia (SPG/OTG), only PACAP has been found in the trigeminal 
system [42]. 
FIGURE 2 immuno (lars) 
 
Early findings of neuropeptide release in primary headaches 
The role of PACAP and VIP is under discussion because (i) they appear jointly in most of the 
SPG/OTG neurons and (ii) PACAP co-localizes with CGRP only in a small fraction of 
neurons within the TG in the small to medium cells. Early studies showed that in migraine 
VIP was only released in a subpopulation of patients that had facial symptoms such as nasal 
congestion, rhinorrhea, and scleral injection in addition to headache (probably due to the 
activation of the trigeminal system). Importantly, all cluster headache subjects showed both 
facial symptoms and VIP release [58]; however, at that time, the methodology to measure 
PACAP was not available. We suggested that this was due to activation of the 
parasympathetic system. Experimental studies in cats [59] revealed that the activation of the 
trigeminal system may in addition involve the parasympathetic system, as denervation of the 
trigeminal nerve aborted the activation of SPG, interpreted either as a direct or indirect 
coupling between these two systems. 
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Involvement of PACAP in migraine 
Conclusions from the studies with PACAP infusion and knockouts 
Human provocation studies of migraine using systemic administration of different 
molecules have generated important insights into the possible mechanisms of headache 
diseases. CGRP, VIP, and PACAP-38 are all strong vasodilators, sharing the activation of 
adenylate cyclase. The first direct evidence that highlighted the potential significance of 
PACAP in the pathophysiology of migraine came from observations made in a human study 
[60], where intravenous administration of PACAP-38 caused headache and vasodilation in 
healthy subjects as well as in migraineurs, and lead to delayed-type migraine-like attacks 
exclusively in migraine patients without aura (65-75%), a feature remarkably similar to that 
previously reported after nitroglycerin infusion [61, 62]. Because VIP had no such effect, it 
was suggested that this might be secondary to the activation of the PAC1 receptor, which is 
now under study in a clinical trial. For comparison, CGRP induces delayed migraine-like 
attacks in 65% of migraine patients, but not in normal subjects [63]. Today numerous CGRP 
active agents are on the verge of going to the market as effective therapy. 
In support of the above, a magnetic resonance imaging (MRI) angiographic study revealed 
that PACAP-38-induced headache was associated with significant dilation of the middle 
meningeal arteries (MMAs), but not of the middle cerebral arteries (MCAs). This effect 
preceded the onset of migraine-like headache and was sensitive to the administration of a 
triptan class of drug [64]. A subsequent MRI angiographic human study demonstrated a 
remarkable and sustained vasodilation of extracranial but not intracranial arteries (including 
the MCAs) following PACAP-38 administration [65]. In addition to these, intravenous 
PACAP-38-induced migraine attacks have been found associated with alterations in brain 
network connectivity, by means of a resting-state functional MRI study [66]. The role of VIP 
in PACAP-induced vasodilation is unclear, as data regarding its levels after PACAP 
administration are contradictory [65, 67], and its vasodilation is less long-lasting than that of 
PACAP [65]. The migraine response to PACAP-38 has not been found to be influenced by 
the presence of the risk allele MEF2D [67, 68]. 
Similar studies on experimental animals support the relevance of PACAP in sensory 
functions as well as in pain disorders, including primary headaches. Neurograms obtained 
following stimulation of the ipsilateral peroneal or sciatic nerve suggested that intrathecal 
PACAP may act as a neurotransmitter or modulator in sensory C-fibers, possibly with a 
contribution of A-fibers [69]. Interestingly, PACAP-27 was more potent than PACAP-38 or 
VIP at this function. On the other hand, the direct intrathecal administration of PACAP 
elicited a dose-dependent decrease in the tail-flick latency, whereas higher doses resulted in 
biting and scratching; these behaviors were interpreted as pain-like syndrome and supported a 
role of PACAP as a sensory neurotransmitter involved in nociception [70]. Intrathecal 
administration of PACAP(6-38), a PAC1 receptor antagonist, however, reduced mechanical 
and thermal hyperalgesia, suggesting that these receptors are important for PACAP-induced 
pain [71]. The role of PAC1 receptor in pain sensation has also been supported by studies 
using PAC1 knockout mice, as these animals showed reduced chronic responses to chemical, 
mechanical, and thermal stimuli [72, 73]. Similar results were obtained with PACAP-
knockout mice, presenting with diminished light-aversive behavior (i.e., photophobia), 
decreased c-fos expression in the TNC and TG, and reduced meningeal blood flow following 
nitroglycerin administration compared to wild-type controls [74]. 
PACAP has also been implicated in higher order processing of pain in brain regions such as 
thalamus and amygdala [75, 76], relevant in the central sensitization and emotional load of 
pain. Supporting the potential role of PACAP in the development of central sensitization of 
pain in migraine, a study demonstrated the ability of an intracerebroventricularly applied 
PAC1 receptor inhibitor to decrease the delayed activation and sensitization of second-order 
nociceptive neurons within the trigeminocervical complex following dural stimulation [77]. 
There are experimental results suggesting the role of PACAP in the development of peripheral 
sensitization as well in certain models of pain [78]. The data on the possible role of PACAP 
and its receptors in migraine pathogenesis by means of modulating neurogenic inflammation 
[73, 79-81] and mast cell degranulation [65, 82-86] are, however, conflicting and at present 
do not enable to draw firm conclusions. 
 
PACAP as a biomarker in primary headaches 
A support for a sensory role of PACAP in nociception came from experiments with 
capsaicin administration in vivo in rats [26], as it resulted in elevated cerebrospinal fluid 
concentrations of PACAP-27 by 177%, PACAP-38 by 93%, and CGRP by 692% [87]. 
Studies on animal models of trigeminal activation confirm the potential role of PACAP in the 
pathogenesis of migraine in particular, as immunoreactivity of both PACAP-27 and PACAP-
38 were found elevated in the TNC of rats following electrical stimulation (at the TG) or 
chemical stimulation (by nitroglycerin) of the trigeminovascular system [88]. Furthermore, 
PACAP-38 levels were also found elevated in the blood plasma of rats after electrical 
stimulation of the TG [88]. Likewise, elevated levels of PACAP were measured in the 
external jugular vein samples of cats following electrical stimulation of the superior sagittal 
sinus [89]. In fact, stimulation of the trigeminal system directly showed the release of not only 
PACAP but also VIP and CGRP into the external jugular venous blood [89, 90]. 
Human clinical studies provide concordant data, as of note, elevated levels of plasma 
PACAP-38 were revealed in the ictal period of migraineurs (i.e., during a spontaneous 
migraine attack) compared to the interictal phase [89, 91]. Interestingly, supportive data were 
reported in episodic cluster headache patients as well [92]. The interictal plasma PACAP 
concentrations of migraineurs were, however, significantly lower compared to the levels 
measured in healthy controls or in patients with tension-type headache [89, 91, 93]. 
 
Concluding remarks 
The exact role of PACAP in primary headaches is still unknown but it is clearly present in 
many different parts of the CNS including several regions of interest in the discussions of 
migraine pathophysiology. Current evidence suggest that PACAP plays essential roles the 
pathogenesis of migraine via modulating the function of nociceptive neurons within the 
trigeminocervical system. 
The position of PACAP in migraine rests on the following main observations: (i) PACAP 
levels are increased in the circulation of cats and rats upon stimulation of the superior sagittal 
sinus [89, 94], and the TG, respectively [88]. (ii) PACAP levels in the external jugular vein 
are reduced with amelioration of migraine headache when subjects were treated with 
sumatriptan, and lower levels of PACAP occur between attacks when compared with attacks 
[89]. (iii) Systemic infusion of PACAP-38 in migraine patients results in migraine-like 
headache [60]. (iv) The plasma levels of PACAP-38 are altered in ictal and interictal periods 
of migraine patients [91]. The unanswered questions that remain are related to the origin of 
endogenous PACAP and the mechanism through which systemic PACAP can induce 
migraine? Though Banks suggests that PACAP does have actions in the CNS and provides 
evidence in support [95], the available data strongly indicate that PACAP does not pass the 
wall of cerebral arteries, as studied in isolated perfused MCAs [96], which agrees with the 
view that the peptide is a large molecule that does not pass the blood-brain barrier (BBB) [96, 
97]. Therefore, as suggested also for CGRP, the relevant target of systemically administered 
PACAP could very well be effects on sites located outside the BBB, such as the TG and other 
ganglia as well as the dura mater; however, this is still not settled, and the role of the BBB 
needs to be clarified. 
Despite the questions that require more comprehensive elucidation in the future, the 
concordant experimental and clinical data on the role of PACAP in the pathogenesis of 
primary headaches, especially migraine, render PACAP and its receptors valuable as potential 
targets of effective future therapeutics. 
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